I find Zacks' pretty useless when it is following young companies with growing revenues, but much faster growing expenses. Insmed has only one "refractory" product (i.e. Arikayce), and its global revenue growth has been slowed by the pandemic. Still, with $928. M in the bank in late June, Insmed's expenses will be growing significantly from here, with its 4 pillared pipeline having to traverse through Phase III trials before applicable drug applications can even be submitted.
The short-term focus here should be on Arikayce global revenue growth, and pipeline progress, not earnings. JMHO.